Acitretin
Acitretin (acitretin) is a small molecule pharmaceutical. Acitretin was first approved as Soriatane on 1996-10-28. It is used to treat psoriasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Acitretin (discontinued: Acitretin, Soriatane)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acitretin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SORIATANE | Stiefel Laboratories | N-019821 DISCN | 1996-10-28 | 4 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acitretin | ANDA | 2024-08-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 3 | 2 | 13 | 9 | 28 |
| Exanthema | D005076 | HP_0000988 | — | — | — | — | 1 | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | — | 1 | — | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | 1 | — | — | 2 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 1 | 1 |
| Basal cell carcinoma | D002280 | — | — | — | — | — | — | 1 | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | — | — | — | 1 | 1 |
| Basal cell nevus syndrome | D001478 | EFO_0004136 | — | — | — | — | — | 1 | 1 |
| Basal cell neoplasms | D018295 | — | — | — | — | — | — | 1 | 1 |
| Keratosis | D007642 | — | — | — | — | — | — | 1 | 1 |
| Palmoplantar keratoderma | D007645 | HP_0000982 | — | — | — | — | — | 1 | 1 |
| Palmoplantar keratoderma diffuse | D015776 | HP_0007447 | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Acitretin |
| INN | acitretin |
| Description | All-trans-acitretin is an acitretin, a retinoid and an alpha,beta-unsaturated monocarboxylic acid. It has a role as a keratolytic drug. |
| Classification | Small molecule |
| Drug class | retinol derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C |
Identifiers
| PDB | — |
| CAS-ID | 55079-83-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1131 |
| ChEBI ID | 50173 |
| PubChem CID | 5284513 |
| DrugBank | DB00459 |
| UNII ID | LCH760E9T7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Acitretin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,849 documents
View more details
Safety
Black-box Warning
Black-box warning for: Acitretin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,801 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use